Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA06 in Advanced Solid Tumors
NCT06372236Phase 1Completed
- Sponsor
- Peking University
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA06 in solid tumor, sponsored by Peking University. Primary endpoints: Maximum Tolerated Dose at 2 years, Preliminary Antitumor Activity at 2 years and 1 more. Started Dec 2023; status: completed.
02
Drugs
UTAA06
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06372236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372236.